Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

The breakup between Novo Nordisk and Hims & Hers remains acrimonious. Recent remarks highlight the competition facing Novo ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...

The timing is also interesting. GLP-1s are Novo Nordisk's biggest and fastest-growing revenue stream, and competition is heating up. Eli Lilly's Zepbound is gaining traction, compounded access is ...

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

Shell (NYSE:SHEL) has denied a report that it is in talks to acquire oil rival BP (NYSE:BP). “This is further market ...

In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...

Scientists at the National Institute of Environmental Health Sciences have found that dog and cat allergens are present in ...

Synthetic food dyes are added to 1 in 5 packaged foods and drinks sold by top U.S. food manufacturers, a new study says.